Biotechnology News

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential...

Lille (France), Cambridge (Massachusetts, United States), September 10, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and...

Lille (France), Cambridge (Massachusetts, États-Unis), le 10 septembre 2026 – GENFIT (Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de...

Adneuris unveiled new abuse potential data demonstrating that cebranopadol's abuse potential may be lower than that of Schedule II and Schedule IV pain drugs, further differentiating its dual NOP/MOP...

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property...

PARAMUS, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery...

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs),...

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...

SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none...